title: Theregen, inc.
abstract: Theregen, Inc. is a regenerative medicine company based in San Francisco, California, USA, that develops cell-based therapies for patients with cardiovascular and vascular disease. The company is conducting a Phase I human clinical safety trial at two US sites for its lead product, Anginera, a cell-based epicardial patch therapy. Anginera is designed to promote blood vessel growth in damaged cardiac tissue, stimulate wound healing and, potentially, to restore cardiac function in patients with heart failure.
authors.affiliation: Theregen, Inc., San Francisco, CA 94104, USA. msianirose@theregencompany.com
authors.forename: Michael
authors.initials: M
authors.lastname: Siani-Rose
mesh_terms: D002318:Cardiovascular Diseases / Q000628:therapy*; D001026:Coronary Artery Bypass; D005347:Fibroblasts / Q000637:transplantation*; D006801:Humans; D017202:Myocardial Ischemia / Q000628:therapy; D044968:Regenerative Medicine; D012495:San Francisco; D014945:Wound Healing / Q000502:physiology*